Sign In
Buy OPORF
$0.350
+0 (+0%)
At Close: Jun 03, 2026
hVIVO selected to run major whooping cough vaccine trial
02:38am, Monday, 27'th Jan 2025
hVIVO PLC (AIM:HVO) has been selected to carry out a large-scale phase III trial for a new whooping cough vaccine, BPZE1, developed by ILiAD Biotechnologies, a late-stage biotech development company
hVIVO lands largest standalone lab contract to date
02:58am, Tuesday, 21'st Jan 2025
hVIVO PLC (AIM:HVO) has secured its largest standalone laboratory contract to date to support a US biotech firm's phase II trial for an influenza drug candidate. The contract is worth £2.7 million, b
hVIVO successfully completes human metapneumovirus pilot
03:00am, Monday, 13'th Jan 2025
hVIVO PLC (AIM:HVO), a company specialising in testing treatments for infectious diseases, has completed a pilot study that could help its clients develop vaccines and medicines for human metapneumov
hVIVO's Covid research showcased in leading scientific journal
02:46am, Thursday, 12'th Dec 2024
hVIVO PLC (AIM:HVO) has announced the publication of findings from the world's first COVID-19 characterisation trial in Nature Communications. The study identified blood-based biomarkers distinguishin
hVIVO secures £11.5m RSV contract and confirms guidance
02:36am, Tuesday, 10'th Dec 2024
hVIVO PLC (AIM:HVO), a specialist contract research organisation, said it had signed a £11.5 million contract as it confirmed financial guidance for the current year. It has struck a deal with a le
hVIVO announces new facility and major field study contract - ICYMI
04:39am, Saturday, 06'th Jul 2024
hVIVO PLC chief executive Mo Khan talked with Proactive about the company's recent developments, including a change of address, the upcoming Capital Markets Day, and new major contracts. Khan highligh
hVIVO deal hailed by brokers; one thinks thinks the stock is worth 60p
08:28am, Tuesday, 02'nd Jul 2024
Shares in hVIVO PLC, the contract research group, rose 2% after it said it had won a contract with an unnamed client to carry out a phase IIb field study assessing an influenza drug candidate. This e
hVIVO lands its largest field study to date as it bags phase II flu trial
04:15am, Tuesday, 02'nd Jul 2024
hVIVO PLC, a specialist contract research group, has been selected as the sole UK clinical site for a phase IIb field study assessing an influenza drug candidate. This evaluation, conducted in collabo
hVIVO deal receives broker seal of approval
08:51am, Monday, 03'rd Jun 2024
The latest contract win by hVIVO PLC has been roundly applauded by brokers. The clinical research has landed a £2.5m characterisation study for a Covid variant from an unnamed mid-tier pharma comp
hVIVO lands £2.5m characterisation study contract for Covid variant
02:47am, Monday, 03'rd Jun 2024
hVIVO PLC (AIM:HVO), a specialist in testing infectious disease products, has signed a £2.5 million contract for an Omicron characterisation study commissioned by a mid-sized pharma company. The eve
hVIVO primed for success, says US investment
04:56am, Friday, 19'th Apr 2024
Stifel, in its latest investment research note, underscores hVIVO PLC's robust standing in the global healthcare market, particularly in conducting human challenge clinical trials (HCTs) for infectiou
hVivo shares remain inexpensive, say analysts
08:54am, Tuesday, 09'th Apr 2024
The hVIVO PLC (AIM:HVO) results and outlook showed how the human challenge trial specialist is well-positioned for further growth, said analysts. Revenues were up 16% to £56 million, as already dis
hVIVO launches annual dividend policy, sets new medium-term growth target
03:35am, Tuesday, 09'th Apr 2024
hVIVO PLC initiated an annual dividend policy as it reported strong earnings growth for last year, with 90% of 2024 revenue already contracted and its new world-beating human challenge trial facility
hVIVO directors to sell stock to meet institutional demand
03:06am, Wednesday, 14'th Feb 2024
hVIVO PLC, a specialist in the field of human challenge clinical trials for infectious and respiratory diseases, said certai directors have agreed to sell shares to meet institutional demand. Involved
CEO Mo Khan on hVIVO's £100m target - ICYMI
04:32am, Saturday, 03'rd Feb 2024
In conversation with Proactive's Stephen Gunnion, hVIVO PLC chief executive Yamin 'Mo' Khan shared insights into the company's impressive financial performance for the year 2023. Amidst a backdrop of
